share_log

Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)

Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)

Avenue Therapeutics | SC 13D/A：超过5%持股股东披露文件(修正)-Fortress Biotech, Inc.(8.0%)
美股sec公告 ·  04/18 04:11
牛牛AI助手已提取核心信息
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
On April 16, 2024, Fortress Biotech, Inc. filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing the acquisition of additional shares in Avenue Therapeutics, Inc. The filing, known as Amendment No. 4, indicates that Fortress Biotech now beneficially owns 3,564,059 shares of Avenue Therapeutics' common stock, which represents approximately 8.0% of the company's outstanding common stock. This ownership includes 250,000 shares of Class A preferred stock, convertible into 16,666 shares of common stock, and 22,222 shares issuable under warrants. The acquisition of 413,507 shares of common stock was part of an Offering Equity Grant resulting from a transaction completed in the first fiscal quarter of 2024. The filing also outlines the rights and conversion details of the Class A preferred stock and the terms of the warrants held by Fortress Biotech's executives. The Amendment No. 4 does not propose any changes to the company's management, structure, or business operations.
2024年4月16日，丰泽生物科技公司向美国证券交易委员会提交了附表13D的修正案，披露了对Avenue Therapeutics, Inc.额外股份的收购。该文件被称为第4号修正案，表明丰泽生物科技现在实益拥有Avenue Therapeutics普通股的3564,059股，约占该公司已发行普通股的8.0％。该所有权包括25万股A类优先股，可转换为16,666股普通股，以及根据认股权证可发行的22,222股股票。413,507股普通股的收购是2024年第一财季完成的交易产生的发行股权补助的一部分。该文件还概述了A类优先股的权利和转换细节以及丰泽生物科技高管持有的认股权证的条款。第4号修正案没有提议对公司的管理、结构或业务运营进行任何更改。
2024年4月16日，丰泽生物科技公司向美国证券交易委员会提交了附表13D的修正案，披露了对Avenue Therapeutics, Inc.额外股份的收购。该文件被称为第4号修正案，表明丰泽生物科技现在实益拥有Avenue Therapeutics普通股的3564,059股，约占该公司已发行普通股的8.0％。该所有权包括25万股A类优先股，可转换为16,666股普通股，以及根据认股权证可发行的22,222股股票。413,507股普通股的收购是2024年第一财季完成的交易产生的发行股权补助的一部分。该文件还概述了A类优先股的权利和转换细节以及丰泽生物科技高管持有的认股权证的条款。第4号修正案没有提议对公司的管理、结构或业务运营进行任何更改。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。